Pharmaceutical Sales Jobs in Japan
62 open permanent sales roles at 28 pharmaceutical companies in Japan, tracked daily from each company's own careers page.
- 28
- 62
- +1
Market Snapshot
Who Is Hiring
Loading openings
Pharmaceutical Sales Jobs in Japan
62 open permanent sales roles at 28 pharmaceutical companies in Japan, tracked daily from each company's own careers page.
62 open permanent sales roles at 28 pharmaceutical companies in Japan, tracked daily from each company's own careers page.
Free to join. Set your terms, stay hidden, and hear only from roles that state them.
Daily total across the 26 companies tracked through the whole period. Companies added mid-period are excluded until the window catches up to them. As of October 7, 2026 · tracked daily since August 1, 2026
Sales, all industries · 1,314 postings with comparable stated pay, from 288 employers
median ¥7,000,000 · 1,314 postings
¥5,400,000
Typical advertised range
¥8,100,000
Postings by Advertised Range
Under ¥4M
28
¥4M–5.9M
306
¥6M–7.9M
508
¥8M–9.9M
306
¥10M–11.9M
110
¥12M–13.9M
32
¥14M–15.9M
12
¥16M+
12
Pharmaceutical Sales-specific pay is hidden: 8 postings state pay, but too few employers disclose to describe a market. Figures appear when enough employers disclose.
How hiring on this page compares with its wider market, on the same measures.
Compared with Pharmaceutical employers across Japan (60 companies).
Counts are per-employer averages; shares are across all live postings on October 6, 2026. English rows use the English-level classification (a subset of postings), so they differ from the share of postings mentioning English in the Market Snapshot. A row is hidden when either side has too few postings to compare fairly.
Counts on this page come from AirTA's own daily checks of each company's careers page. When a number cannot be measured reliably, it is hidden rather than estimated. Industry describes the company, not the individual role, so an employer with several businesses appears under each industry it operates in. Report a data issue.